Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
BioArctic’s partner Eisai will present new long-term, real-world data on the Alzheimer’s drug lecanemab at the AD/PD 2026 congress in Copenhagen, including four-year results from the Clarity AD open-label extension and multiple analyses of safety, effectiveness and biomarker correlations. BioArctic will contribute an oral presentation on lecanemab’s mechanism of action and a poster on exidavnemab in Parkinson’s disease, underscoring the company’s expanding clinical and scientific footprint in neurodegenerative disorders and its efforts to validate antibody therapies in both Alzheimer’s and Parkinson’s care.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK342.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company focused on neurodegenerative diseases, developing antibody-based therapies for conditions such as Alzheimer’s and Parkinson’s. The company collaborates closely with partners like Eisai to advance disease-modifying treatments targeting pathological proteins in the central nervous system.
Average Trading Volume: 214,781
Technical Sentiment Signal: Buy
Current Market Cap: SEK28.44B
For a thorough assessment of BIOA.B stock, go to TipRanks’ Stock Analysis page.